[Risk factors for cytomegalovirus in solid organ transplant recipients].

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Enfermedades Infecciosas y Microbiologia Clinica

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0213-005X(11)70051-9PMID 22541916
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ganciclovir

  2012cited by this paper
• Mannose-binding lectin and ficolin-2 gene polymorphisms predispose to cytomegalovirus (re)infection after orthotopic liver transplantation.

  2011cited by this paper
• Therapeutic Effect of the Acquisition of Cytomegalovirus-Specific Immune Response During Preemptive Treatment

  2011cited by this paper
• Alemtuzumab induction in renal transplantation.

  2011cited by this paper
• Epidemiology and risk factors for late infection in solid organ transplant recipients

  2011cited by this paper
• Lectin complement pathway gene profile of donor and recipient determine the risk of bacterial infections after orthotopic liver transplantation

  2010cited by this paper
• Extended Valganciclovir Prophylaxis in D+/R− Kidney Transplant Recipients is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study

  2010cited by this paper
• Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study

  2010cited by this paper
• Defining the Risks for Cytomegalovirus Infection and Disease After Solid Organ Transplantation

  2010cited by this paper
• IL-6 and TNF-alpha synergistically inhibit allograft acceptance.

  2009cited by this paper
• High frequency of clinically significant infections and cytomegalovirus disease in kidney transplant recipients with serum mannose-binding lectin deficiency.

  2009cited by this paper
• A Multicenter Study of Valganciclovir Prophylaxis up to Day 120 in CMV‐Seropositive Lung Transplant Recipients

  2009cited by this paper
• A new strategy of delayed long‐term prophylaxis could prevent cytomegalovirus disease in (D+/R−) solid organ transplant recipients

  2009cited by this paper
• An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants.

  2009cited by this paper
• Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection.

  2009cited by this paper
• The R753Q polymorphism abrogates toll-like receptor 2 signaling in response to human cytomegalovirus.

  2009cited by this paper
• Influence of mannose-binding lectin gene polymorphisms on the invasiveness of cytomegalovirus disease after solid organ transplantation.

  2009cited by this paper
• Donor mannose‐binding lectin gene polymorphisms influence the outcome of liver transplantation

  2009cited by this paper
• Donor mannose-binding lectin deficiency increases the likelihood of clinically significant infection after liver transplantation.

  2009cited by this paper
• Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease.

  2009cited by this paper
• Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation.

  2008cited by this paper
• Impact of the complement lectin pathway on cytomegalovirus disease early after kidney transplantation.

  2008cited by this paper
• Cytomegalovirus infection after liver transplantation: current concepts and challenges.

  2008cited by this paper
• Prevention of cytomegalovirus disease using preemptive treatment after solid organ transplant in patients at high risk for cytomegalovirus infection

  2008cited by this paper
• Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation.

  2008cited by this paper
• Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression.

  2008cited by this paper
• Association of the outcome of renal transplantation with antibody response to cytomegalovirus strain-specific glycoprotein H epitopes.

  2007cited by this paper
• Risk Factors for Hospitalization for Bacterial or Viral Infection in Renal Transplant Recipients—An Analysis of USRDS Data

  2007cited by this paper
• Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation.

  2007cited by this paper
• [Immunosuppression and infection in transplant recipients].

  2007cited by this paper
• Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation.

  2007cited by this paper
• Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.

  2007cited by this paper
• Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody.

  2007cited by this paper
• TH1/TH2 cytokine release pattern during in vivo cytomegalovirus disease in solid organ transplantation.

  2007cited by this paper
• The Influence of Innate Immunity Gene Receptors Polymorphisms in Renal Transplant Infections

  2007cited by this paper
• Induction Immunosuppression

  2006cited by this paper
• Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy

  2006cited by this paper
• Hypogammaglobulinemia in Liver Transplant Recipients: Incidence, Timing, Risk Factors, and Outcomes

  2006cited by this paper
• Rabbit antithymocyte globulin versus basiliximab in renal transplantation.

  2006cited by this paper
• Seroprevalence of cytomegalovirus infection in the United States, 1988-1994.

  2006cited by this paper
• Relevance of Toll-like receptor-4 polymorphisms in renal transplantation.

  2005cited by this paper
• Hypogammaglobulinemia after heart transplantation: use of intravenous immunoglobulin replacement therapy in relapsing CMV disease.

  2005cited by this paper
• Clinical Utility of Cytomegalovirus (CMV) Serology Testing in High‐risk CMV D+/R− Transplant Recipients

  2005cited by this paper
• Outcome, Incidence, and Timing of Infectious Complications in Small Bowel and Multivisceral Organ Transplantation Patients

  2005cited by this paper
• Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation.

  2005cited by this paper
• Late-Onset Cytomegalovirus Disease in Liver Transplant Recipients Despite Antiviral Prophylaxis1

  2004cited by this paper
• Is there a change in cytomegalovirus seroepidemiology in Spain?

  2004cited by this paper
• Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials1

  2004cited by this paper
• Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients

  2004cited by this paper
• Impact of mannose-binding lectin on susceptibility to infectious diseases.

  2003cited by this paper
• Toll-Like Receptor Ligands Modulate Dendritic Cells to Augment Cytomegalovirus- and HIV-1-Specific T Cell Responses 1

  2003cited by this paper
• A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients1

  2003cited by this paper
• Analysis of the Relationship Between Mannose‐Binding Lectin (MBL) Genotype, MBL Levels and Function in an Australian Blood Donor Population

  2002cited by this paper
• Mycophenolate mofetil immunosuppressive therapies increase the incidence of cytomegalovirus infection in renal transplantation.

  2002cited by this paper
• Infections in Renal Transplant Recipients Receiving Mycophenolate Versus Azathioprine-Based Immunosuppression

  2002cited by this paper
• Infectious complications of lung transplantation

  2001cited by this paper
• Hypogammaglobulinemia following cardiac transplantation: a link between rejection and infection.

  2001cited by this paper
• Cytomegalovirus in solid organ transplantation

  2001cited by this paper
• Toll-like receptors: critical proteins linking innate and acquired immunity

  2001cited by this paper
• In vitro cytokine production of TNFalpha and IL-13 correlates with acute liver transplant rejection.

  2001cited by this paper
• Association of human herpesvirus 6 reactivation with severe cytomegalovirus-associated disease in orthotopic liver transplant recipients.

  2001cited by this paper
• Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.

  2001cited by this paper
• RISK FACTORS AND IMPACT OF CYTOMEGALOVIRUS DISEASE IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION

  2001cited by this paper
• A PROSPECTIVE STUDY OF THE NATURAL COURSE OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN RENAL ALLOGRAFT RECIPIENTS1

  2000cited by this paper
• Valganciclovir Results in Improved Oral Absorption of Ganciclovir in Liver Transplant Recipients

  2000cited by this paper
• Distinct Pathways of Mannan-Binding Lectin (MBL)- and C1-Complex Autoactivation Revealed by Reconstitution of MBL with Recombinant MBL-Associated Serine Protease-21

  2000cited by this paper
• Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

  2000cited by this paper
• Prospective study of human betaherpesviruses after renal transplantation: association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection.

  2000cited by this paper
• Preemptive treatment approach to cytomegalovirus (CMV) infection in solid organ transplant patients: relationship between compliance with the guidelines and prevention of CMV morbidity

  2000cited by this paper
• Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients

  2000cited by this paper
• Human herpesvirus-6 is associated with cytomegalovirus reactivation in liver transplant recipients.

  2000cited by this paper
• Human herpesviruses 6 and 7 as potential pathogens after liver transplant: Prospective comparison with the effect of cytomegalovirus

  1999cited by this paper
• Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

  1999cited by this paper
• Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.

  1998cited by this paper
• Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection.

  1998cited by this paper
• Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function.

  1998cited by this paper
• Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

  1997cited by this paper
• Infectious complications after OKT3 induction in liver transplantation.

  1997cited by this paper
• Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors.

  1997cited by this paper
• Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients

  1997cited by this paper
• Latent and persistent infections of monocytes and macrophages.

  1996cited by this paper
• Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression.

  1995cited by this paper
• Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation.

  1995cited by this paper
• Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection.

  1995cited by this paper
• Infectious complications following pancreatic transplantation: incidence, microbiological and clinical characteristics, and outcome.

  1995cited by this paper
• Cytomegalovirus after heart transplantation. Risk factors for infection and death: a multiinstitutional study. The Cardiac Transplant Research Database Group.

  1994cited by this paper
• CYTOMEGALOVIRUS INFECTION IN TRANSPLANT RECIPIENTS THE ROLE OF TUMOR NECROSIS FACTOR

  1994cited by this paper
• Prevalence of Invasive Cytomegalovirus Disease with Administration of Muromonab Cd-3 in Patients Undergoing Orthotopic Liver Transplantation

  1992cited by this paper
• Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes.

  1991cited by this paper
• Human herpesvirus 6 induces interleukin-1 beta and tumor necrosis factor alpha, but not interleukin-6, in peripheral blood mononuclear cell cultures

  1991cited by this paper
• The human mannose-binding protein functions as an opsonin

  1989cited by this paper
• A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants.

  1985cited by this paper

• CMV Infection Risk Factors and Viral Dynamics After Valganciclovir Prophylaxis: 10 Years of Experience in Lung Transplant Recipients

  2024cites this paper
• Cytomegalovirus Viremia in Solid-Organ Transplant Patients in the First Year After Transplantation.

  2022cites this paper
• Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice

  2021cites this paper
• Contribution of Population Pharmacokinetics to Dose Optimization of Ganciclovir-Valganciclovir in Solid-Organ Transplant Patients

  2016cites this paper
• Eficacia y seguridad de Ganciclovir y Valganciclovir en el manejo de la infección por citomegalovirus en el trasplante de órgano sólido

  2016cites this paper